Key points from article :
CollPlant reached a milestone of $10 million in its collab with AbbVie for a regenerative dermal and soft tissue filler.
Collaboration began in 2021 for dermal and soft tissue filler products in the medical aesthetics market.
CollPlant’s recombinant human collagen (rhCollagen) technology is a key component of these products.
AbbVie granted a global license to combine rhCollagen with its proprietary technologies to produce & market fillers.
“CollPlant’s rhCollagen is non-immunogenic and non-allergenic, and enables tissue regeneration,” said Yehiel Tal, CEO of CollPlant.
Eligible to receive up to $26 million for dermal fillers, as well as royalty payments & manufacturing fees for rhCollagen supply.
As well as medical aesthetics, CollPlant is focused on developing products for 3D bioprinting of tissues and organs.
